AstraZeneca, Bristol Myers Hold Talks on Potential $400 Billion Merger

According to reporting by The Guardian, AstraZeneca has held talks with Bristol Myers Squibb about a transaction that could value the combined company at roughly $400 billion, though the discussions remain preliminary and may not result in an agreement.

If completed, the merger would create one of the world’s largest drugmakers and significantly expand AstraZeneca’s presence in the United States while combining two companies with major portfolios of cancer medicines, according to The Guardian.

Analysts cited by The Guardian said any deal would likely face close examination from antitrust regulators because both companies have substantial oncology businesses, raising questions about competition in several therapeutic markets. They also questioned whether a merger of that scale would produce meaningful strategic benefits or complicate research and development efforts.

Related: AstraZeneca, Pfizer, and Sanovel Among 17 Drugmakers Fined by Turkish Regulator

Investor reaction reflected some of those concerns. According to The Guardian, AstraZeneca shares fell more than 7% after the report, while Bristol Myers Squibb shares gained about 3.5%.

The Guardian reported that AstraZeneca has been pursuing expansion in the U.S. market under Chief Executive Pascal Soriot, including a previously announced plan to invest $50 billion in U.S. operations by 2030. The company has also said it aims to reach $80 billion in annual revenue by the end of the decade.

Source: The Guardian